Podcasts about hiv prep

The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be left up to the U.S. Preventive Services Task Force. The ruling thwarted a lawsuit brought by a group of insurance providers who challenged the Affordable Care Act's requirement that they cover preventive medicines, such as HIV drugs, recommended by the task force. The high court also determined that members of this task force can be removed at will by HHS Secretary Robert F. Kennedy Jr.Speaking of HHS committees from which members have been removed at will by Kennedy, the CDC's revamped Advisory Committee on Immunization Practices convened last week for its first meeting since the roster overhaul, where a vote on Merck's recently approved RSV-targeting monoclonal antibody Enflonsia and a discussion around the inclusion of preservative thimerosal in influenza vaccines was on the docket, but an expected vote on Moderna's mRNA-based RSV shot mRESVIA was not.Also dominating the headlines on Friday was the FDA's decision to remove the Risk Evaluation and Mitigation Strategies (REMS) program from the six approved CAR T therapies it was applied to. Analysts and patient groups lauded the move, which is expected to potentially double access to these life-saving therapies, saying it reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”Willliam Blair noted that it could be a “positive signal” to companies developing CAR T therapies for autoimmune diseases, which now includes AbbVie. In an all-cash buyout on Monday, the Illinois-based pharma dropped $1.2 billion for Capstan Therapeutics and its in vivo edited CAR T therapy for B cell–mediated autoimmune diseases. M&A has been on an uptick of late, and private equity companies—such as those that snapped up bluebird bio—are also getting in on the game.Finally, after Lykos Therapeutics' high profile failure last summer, the psychedelics space is heating up once again. While a Phase III readout of Compass Pathways' psilocybin drug last week in treatment-resistant depression received a muted reaction from investors, the response to a Phase II readout for Beckley Psytech and atai Life Sciences' intranasal psychedelic was more positive.

Shalom! Today, travel medicine specialists Drs. Paul Pottinger ("Germ") & Chris Sanford ("Worm") answer your travel health questions:Traveler's Diarrhea: How to avoid it, and will treatment help prevent complications? Can I catch leprosy from an armadillo?Rabies: Can I tell from an animal's behavior whether it is rabid?Dengue fever vaccines: is that a thing?Is it safe to use loperamide when I get traveler's diarrhea?Should I use a condom even if I'm already on HIV PrEP?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please send us your questions and travel health anecdotes: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

Why is it so hot? What's the best sunscreen? Can you get addicted to your phone? What is the latest breakthrough in HIV drugs? Was there a food recall? Covering the latest news in HIV treatment, a listeria outbreak, staying safe during the summer heatwave, and social media and adolescent phone addiction with AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. American Medical Association CXO Todd Unger hosts.

In der neuen Podcast-Folge der Reihe „Wissenschaft trifft Praxis“ diskutiert unsere Referentin für Infektionsschutz und Hygiene, Dr. Sybille Somogyi, mit ihren Gästen wieder Fragen zu einem aktuellen Thema: Dieses Mal zur HIV Prä-Expositions-Prophylaxe (PrEP) – Was kann PrEP leisten, wie sinnvoll ist es, eine PrEP-Sprechstunde zu etablieren, wie kann der ÖGD unterstützen? PrEP ist eine Therapieform, die als Vorsorge vor einer Ansteckung mit dem HIV-Virus eingesetzt wird. Sie hat sich seit ihrer Zulassung in der EU im Jahr 2016 zu einer etablierten und zuverlässigen Säule der HIV-Prävention entwickelt. In mehreren Städten wird PrEP im ÖGD schon seit vielen Jahren rezeptiert und betreut. Für Menschen mit Krankenversicherung werden Kosten und die begleitenden Untersuchungen durch die gesetzlichen Krankenkassen übernommen. Aber wie sieht es für Menschen ohne Zugang zum Regelgesundheitssystem aus? Das ist ein großes Thema in dem neuen Podcast.Es geht aber auch um die Frage, was sich aus der Datenlage des Robert Koch-Instituts in Berlin (RKI) ableiten lässt und wie hilfreich es wäre, trotz möglicher Bedenken eine PrEP-Beratung zu etablieren. Zudem gibt es Tipps für eine solche PrEP-Sprechstunde und die Forderung nach einer breiteren PrEP-Versorgung im und durch den ÖGD.Die Gäste der Podcast-Folge beschäftigen sich schon lange intensiv mit dem aktuellen Thema:Dr. Daniel Schmidt, Epidemiologe im Fachgebiet HIV und weitere sexuell übertragbare Erkrankungen am Robert Koch-Institut in BerlinGerhard Schlagheck, Dipl.-Sozialarbeiter in der Beratungsstelle CASAblanca, Centrum für HIV und sexuell übertragbare Infektionen in Hamburg-AltonaDr. Tessa Winkel, Fachärztin für Gynäkologie und Geburtshilfe im Zentrum für sexuelle Gesundheit und Familienplanung in Berlin-Charlottenburg-WilmersdorfLinks & Quellenhttps://register.awmf.org/de/leitlinien/detail/055-008https://www.aidshilfe.de/hiv-prephttps://www.liebesleben.de/fuer-alle/hiv-aids/prep/https://www.bundesgesundheitsministerium.de/terminservice-und-versorgungsgesetz/prep.htmlhttps://www.aidshilfe.de/medien/md/was-brauchen-sexarbeiterinnen-fuer-ihre-gesundheit/https://iris.who.int/bitstream/handle/10665/360861/9789240053694-eng.pdf?sequence=1Der Akademie-Podcast „Wissenschaft trifft Praxis“ erscheint im Wechsel mit dem zweiten regelmäßigen Akademie-Podcast „Akademie-Journal“. Du kannst die Podcasts auf unserer Website sowie auf allen Podcast-Portalen hören.Mehr Podcasts und Publikationen der Akademie finden Sie in unserer Mediathek. Wir freuen uns auf Ihr Feedback an: redaktion@akademie-oegw.de

In this special episode, Kiki and Medinah sit down with AID Atlanta to talk all things HIV awareness, testing, and community care. From prevention to treatment to removing the stigma, this episode is packed with information every sexually active adult needs to hear. Follow Us@cocktalespodcast@kikisaidso@coffeebeandeanFollow AID Atlanta @aid_atlantaEpisode Subtitle:Real Talk on HIV, Sex, and Self-Advocacy with AID Atlanta Topics Covered:The difference between HIV and AIDSHow transmission actually happens (spoiler: it's not just through sex)The life-changing impact of PrEP and PEPWhat it means to be undetectable and why U=U mattersBreaking down stigma and misconceptions (especially in Black and brown communities)Resources available at AID Atlanta — from testing and mental health services to support groups and volunteer opportunitiesWhy getting tested regularly should be part of your self-care routineHow community, support, and education can empower people living with HIVA candid sponsor break on Pantydeal — a sex-positive, anonymous, and safe way to make money online while exploring kinksResources & Links:

New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.

This podcast outlines some of the data presented at the 25th International AIDS Conference from HPTN 084 as it pertains to using injectable cabotegravir for HIV PrEP during pregnancy. Related Content:  https://www.hptn.org/research/studies/hptn-084 https://programme.aids2024.org/Programme/Session/349 CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/

The Getting2U (G2U) crew get the chat with Dr. AC Demidont. Medical Scientist for Gilead Sciences. The team met with Dr. AC Demidont to discuss the latest on HIV PrEP and the studies involved in approving these medications. Dr. Demidont shared her knowledge and input on the current state of HIV PrEP and the importance … Read More Read More

Pyritz, Lennart www.deutschlandfunk.de, Sprechstunde

In der 88. Folge des Infektiopods präsentieren wir Highlights von der ID Week – dem infektiologischen Kongress in den USA. Till war dort, hat O-Töne von bekannten Infektiologinnen und Infektiologen eingefangen und hat News zu spannenden Themen mitgebracht: In dieser Folge geht es um Neuigkeiten zu RSV-Impfungen, HIV-Prep mit Lenacapavir, Dalbavancin im DOTS-Trail und verkürzter … „Infektiopod #88: News von der ID Week“ weiterlesen

Today we will discuss if screening asymptomatic Men who have sex with Men, also referred to as MSM, who are receiving HIV pre-exposure anti-retroviral medication, called HIV PrEP, routinely for bacterial STIs, gonorrhoea and chlamydia through pharyngeal, urine and rectal PCR testing every three months- also referred to as 3x3 testing is indeed of benefit or may cause harm. This year, in Lancet HIV, the Gonoscreen trial, a randomised controlled trial, of 500 MSM on PrEP in each arm followed up for 12 months reported that 3x 3 testing does not reduce the incidence of gonorrhoea and chlamydia infections in this specific cohort. In Belgium, this trial has led to a change in clinic practice through the Belgium HIV PrEP guidelines where patients will be screened less frequently and intensely. Lancet ID on the other hand published an opinion piece by Raccagni et al where concerns about transmission and morbidity risk of untreated infection and implications of using poor quality screening tools are voiced. We will discuss today the merit of the Gonoscreen trial and other studies that support a decrease in screening & treating asymptomatic bacterial STIs and exercising stricter antimicrobial stewardship versus the risks associated with leaving asymptomatic infections untreated and risking morbidity and transmission. Relevant links: Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial Primum non-nocere: Is it time to stop screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men taking HIV pre-exposure prophylaxis? The arrested immunity hypothesis in an immunoepidemiological model of Chlamydia transmission Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues Host: Dr Fabiola Martin, Sexual Health Specialist and Associate Professor, Australian National University, Canberra, Australia Dr Thibaut Vanbaelen, physician and post-doctoral researcher at The Institute of Tropical Medicine in Antwerp, Belgium Dr Angelo Roberto Raccagni, physician at Vita-Salute San Raffaele University in Milan, Italy

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sanofi has signed a $326 million deal with Orano Med for radiopharma, following a similar deal made in September. Sage Therapeutics is laying off 33% of employees to support the launch of its postpartum depression drug. Bristol-Myers Squibb's Opdivo showed a progression-free survival advantage over Pfizer's Adcetris in a late-stage study for Hodgkin's lymphoma. Kezar Life Sciences has cut its lupus program after patient deaths and is now focusing on autoimmune hepatitis. The Institute for Clinical Research is researching ways to extend healthy lifespan. Other news includes GSK and Viiv touting the effectiveness of a long-acting HIV prep, Bavarian Nordic's Jynneos eliciting a robust antibody response in adolescents, and AbbVie winning approval for an advanced Parkinson's treatment. Takeda has walked away from a partnership for Huntington's disease after investing $260 million.

“This podcast discusses the recent presentation of data for lenacapavir, a potent capsid inhibitor for HIV that was 100% effective in preventing HIV infection in cis-gender woman at risk for HIV. If approved, it will offer an exciting new option to prevent HIV which should dramatically improve our chances of reaching the goal of totally eliminating new HIV infections.  The trial compared twice yearly injections of lenacapavir to both F/TAF and F/TDF in cis-gender woman and found similar effectiveness for F/TAF compared to F/TDF but there were zero new HIV infections in participants on lenacapavir.”. Related Content:  The New England Journal of Medicine. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. Authors: Linda-Gail Bekker, M.B., Ch.B, Ph.D. https://orcid.org/0000-0002-0755-4386, Moupali Das, M.D., M.P.H., Quarraisha Abdool Karim, Ph.D. https://orcid.org/0000-0002-0985-477X, Khatija Ahmed, M.B., B.Ch., Joanne Batting, M.B., Ch.B., D.F.S.R.H., D.R.C.O.G., Dip. HIV Man., William Brumskine, M.B., Ch.B., Dip. HIV Man., Katherine Gill, M.B., Ch.B., M.P.H., +33, for the PURPOSE 1 Study Team*Author Info & Affiliations. Published July 24, 2024. DOI: 10.1056/NEJMoa2407001 CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/

This episode discusses four recent articles about lymphogranuloma venereum (LGV) including the effectiveness of a 7-day doxycycline course and the increasing prevalence of asymptomatic LGV in the era of HIV PrEP. View episode transcript and references at www.std.uw.edu.This podcast is dedicated to an STD [sexually transmitted disease] review for health care professionals who are interested in remaining up-to-date on the diagnosis, management, and prevention of STDs. Editor and host Dr. Meena Ramchandani is an Assistant Professor of Medicine at the University of Washington (UW) and Program Director of the UW Infectious Diseases Fellowship Program. 

What does the body of evidence say on LASIK, the use of lasers to correct vision? Plus: many men on PreP are abandoning condoms as STIs are becoming more common, and Chris tells us if krill oil can cure arthritis of the knee. Also, Jonathan briefly imitates Alex Jones. A Block: LASIK (0:59) How lasers are used in medicine; LASIK and its cousins; how to choose; effectiveness, satisfaction, and side effects. B Block: HIV PrEP and STIs (28:18) How does pre-exposure prophylaxis against HIV works, and what is simultaneously happening with condom use (going down) and rates of STIs (going up). Also, what is Doxy-PEP? C Block: Krill Oil for Knee Osteoarthritis (44:45) An Australian trial of krill oil for arthritis of the knee came to the conclusion that… well, what do you think? * Theme music: “Fall of the Ocean Queen“ by Joseph Hackl * Assistant researcher: Aigul Zaripova   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/. To make a one-time donation to our show, you can now use PayPal! https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Patrons get a bonus show on Patreon called “Digressions”! Check it out!   References: Comparisons of LASIK and its related techniques: 1) DOI: 10.1371/journal.pone.0174810  2) DOI: 10.1016/j.jcrs.2007.07.026  3) DOI: 10.1136/bjo.2007.131748  4) DOI: 10.1016/j.ajo.2017.03.013  5) DOI: 10.1002/14651858.CD012687.pub2    Outcomes from LASIK: 6) DOI: 10.1016/s0161-6420(99)00148-7  7) DOI: 10.1016/s0161-6420(00)00528-5  8) doi:10.1001/jamaophthalmol.2016.4587   UpToDate entries pertaining to HIV, PrEP, and Doxy-PEP: 9) https://www.uptodate.com/contents/hiv-pre-exposure-prophylaxis 10) https://www.uptodate.com/contents/primary-care-of-gay-men-and-men-who-have-sex-with-men 11) https://www.uptodate.com/contents/prevention-of-sexually-transmitted-infections 12) https://www.uptodate.com/contents/hiv-infection-risk-factors-and-prevention-strategies   13) Statistics Canada survey of sexually active 15-to-24-year-olds: https://www150.statcan.gc.ca/n1/pub/82-003-x/2020009/article/00001-eng.htm 14) Increased rates of STIs according to Public Health Agency of Canada: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/report-sexually-transmitted-infection-surveillance-canada-2019.html 15) Systematic review and meta-analysis on sexual risk behaviour in men who use PrEP: https://doi.org/10.1093/cid/ciy182 16) Australian trial on krill oil for knee osteoarthritis: https://doi.org/10.1001/jama.2024.6063   It's Not Twitter But It'll Do: 1) Jonathan's article about Lumina to avoid dental cavities: https://www.mcgill.ca/oss/article/medical-critical-thinking-technology/reports-death-dental-cavities-are-greatly-exaggerated 2) The Skeptics' Dictionary: https://www.skepdic.com/  

Deputy Editor Adrian Gonzalez interviews Manik Kohli (Institute of Global Health at the University College London, UK), Iain Reeves (Homerton Healthcare NHS Trust, UK), and Laura Waters (Central and North West London NHS Trust, UK) on how homophobia results in limitations to accessing effective interventions such as HIV PrEP, mpox vaccination and DoxyPEP.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00302-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhivContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, David Saunders discusses the value of nonstigmatizing discussions between people using HIV pre-exposure prophylaxis (PrEP) and healthcare professionals, including: Encouraging accountability to individualize adherence strategies and improve persistence to PrEPReducing stigma, discrimination, and prejudice in healthcare settings to foster PrEP persistence Faculty: David SaundersPrEP User and AdvocateLink to full program:https://bit.ly/3ZlICsLTo automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast.

In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including: The importance of having PrEP navigators to help with logistics and be a point of contact for patients Where to find education and resources to familiarize yourself with PrEP and its prescribingSafety considerations and adverse events associated with PrEP optionsPrEP coverage and costHow to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEPFacultyTavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaAnne Teitelman, PhD, FNP-BC, FANNP, FAANAssociate Professor Emeritus of Nursing and Global Women's HealthDepartment of Family and Community HealthSchool of NursingUniversity of PennsylvaniaProfessorThomas Jefferson UniversityCollege of NursingPhiladelphia, PennsylvaniaLink to full program: https://bit.ly/3PZGYdR

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:Available training resources on how to offer PrEP in primary careAffordable, accessible PrEP options, including patient assistance programsUsing electronic health records to identify candidates for PrEPOpportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concernsHow to offer 3-site STI testing at your facilityWrapping PrEP into primary careIncorporating navigators or care coordinators to reduce logistical barriers and reach underserved populationsRapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visitsHealthcare professionals' personal biases as a potential barrier to PrEPUsing ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billingFaculty:Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaJona Tanguay, MMSc, PA-C, AAHIVSMedical Program Lead - Substance Use Disorders at Whitman-Walker HealthAssociate Medical Director - Transgender Health at Amida CarePresident-Elect at GLMA: Health Professionals Advancing LGBTQ+ EqualityClinical Instructor at Yale School of MedicineFounder at ChemsexHarmReduction.orgWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, Meredith Clement, MD, and Whitney C. Irie, MSW, PhD, discuss key considerations for pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: How to incorporate conversations on PrEP during a short clinic visit Helpful resources about PrEP to share with patientsLeveraging clinic staff to improve PrEP uptake and persistence Available data on on-demand PrEPApproach to discussing PrEP contraindications and adverse events with patientsConsiderations for PrEP in pregnant persons or those wanting to conceive The importance of inclusiveness in PrEP marketing Key barriers limiting PrEP uptake in cisgender women (eg, stigma, risk perception)Interventions to improve PrEP uptakeFacultyMeredith Clement, MDAssociate Professor Infectious Diseases Louisiana State University Health Sciences CenterNew Orleans, Louisiana Whitney C. Irie, MSW, PhDAssistant ProfessorDepartment of Social WorkBoston CollegeBrighton, Massachusetts Link to full program: https://bit.ly/3PZGYdR

In this episode, Samantha V. Hill, MD, MPH, and Eunice E. Radcliff, MD, discuss key considerations for PrEP uptake in adolescents, including: Advice on talking with parents about the importance of adolescents having alone time with their healthcare professionalsMaintaining confidentiality when someone is on their parents' insuranceStrategies to increase awareness, uptake, engagement, and persistence on PrEP among adolescentsHaving discussions about HIV prevention and PrEP along with the HPV vaccine, STI testing, or contraceptionFacultySamantha V. Hill, MD, MPHAssistant ProfessorDivision of General PediatricsSection on Adolescent HealthDepartment of PediatricsEmory UniversityAtlanta, GeorgiaEunice E. Radcliff, MDAssistant Professor General PediatricsEmory University School of MedicineAtlanta, GeorgiaLink to full program: https://bit.ly/3PZGYdR

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Data on drug–drug interactions between PrEP options and gender-affirming hormone therapyContributing factors to inequities in PrEP uptake for Black and Latino individualsData on FTC/TAF PrEP for transgender individualsHow to decide whether to do an oral lead-in before starting injectable cabotegravir PrEPTime to effectiveness after starting PrEP PrEP resources available for transgender communities, especially regarding stigmaIntegration of PrEP with gender-affirming hormone therapyStrategies to increase PrEP uptake, specifically in the southCounseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEPInvolving PrEP navigators in the care of people receiving PrEPSupporting PrEP adherence and retention in careThe use of DoxyPEP in transgender individuals receiving PrEPFacultyAniruddha (Anu) Hazra, MDAssistant Professor, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicDirector of STI Services, Chicago Center of HIV EliminationDepartment of MedicineUniversity of ChicagoChicago, IllinoisOfole Mgbako, MDAssistant Professor of Medicine and Population Health  Section Chief of Infectious DiseaseBellevue HospitalClinical Pillar Lead, NYU Institute for Excellence in Health EquityNYU Grossman School of MedicineNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3PZGYdR

In this podcast, experts Sarah M. Wood, MD, MS, and Errol L. Fields, MD, PhD, MPH, discuss some of the challenges and concerns clinicians face when prescribing PrEP to adolescents. The faculty addresses the potential for adverse effects from PrEP, including the potential for renal impairment, decreased bone density, and whether PrEP can interfere with hormone therapy for gender-affirming care. They review the data behind these concerns and emphasize that the vast majority of adverse effects caused by PrEP are mild and reversible.The experts also examine common barriers that adolescents face when attempting to initiate and adhere to PrEP, such as insurance coverage and confidentiality. Dr Fields and Dr Woods discuss strategies for overcoming these barriers and retaining adolescents on PrEP, including how to navigate tricky conversations with both patients and parents or within communities that may stigmatize PrEP and HIV.Sarah M. Woods, MD, MSAssistant Professor of PediatricsDivision of Adolescent MedicineUniversity of Pennsylvania Perelman School of MedicineChildren's Hospital of PhiladelphiaPhiladelphia, PennsylvaniaErrol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandContent based on an online CME program supported by independent educational grants from Gilead Sciences Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR

In this episode, David Alain Wohl, MD, discusses key considerations to PrEP barriers in cisgender women, including:Prevalence of PrEP use in the USBarriers to PrEP uptake PrEP efficacy based on adherenceInterventions to support PrEP adherenceRecommended PrEP regimens, including considerations for use in pregnancy and breastfeeding Presenter: David Alain Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel Hill Chapel Hill, North Carolina Content based on an online CME program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3ZpM6uuFollow along with the slides: https://bit.ly/3LyGgBj

In this episode, Oni Blackstock, MD, MHS, and Whitney Irie, MSW, PhD, discuss key considerations for PrEP uptake in cisgender women, including: Ways to perform a nonintimidating sexual history How to incorporate conversations on PrEP during a short clinic visit Discussing adverse events associated with PrEP options with patientsConsiderations for PrEP in women wanting to conceive How patients can navigate obtaining PrEP in areas with limited healthcare resources Guideline recommendation updates on PrEP eligibility Use of wrap-around services Interventions to improve PrEP access (eg, telehealth, nurse-led PrEP)FacultyOni Blackstock, MD, MHSFounder & Executive DirectorHealth JusticeNew York, New YorkWhitney Irie, MSW, PhDAssistant ProfessorDepartment of Social WorkBoston CollegeBrighton, Massachusetts Link to full program: https://bit.ly/3PZGYdR

In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations to PrEP barriers in adolescents, including: New HIV diagnoses in the United StatesAdherence barriersHealthcare professional barriersConsent laws for minors to receive sexually transmitted infection diagnosis and treatment services Interventions to support PrEP adherence Presenter: Roger Bedimo, MD, MS, FACPProfessor of MedicineDivision of Infectious DiseasesUniversity of Texas UT Southwestern Medical CenterSection ChiefDepartment of Internal MedicineVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZpM6uuFollow along with the slides:https://bit.ly/3LyGgBj

In this episode, Jill Blumenthal, MD, MAS, and Kenric B. Ware, PharmD, MBA, AAHIVP, answer questions about HIV PrEP including:Considerations for selecting between oral and injectable PrEP in college studentsStrategies to promote PrEP persistence in adolescents Best approaches to address readiness to start PrEP in adolescents (eg, creating nonjudgmental environments, addressing misconceptions)Considerations for local consent lawsAvailable data on PrEP young adolescents (eg, age and weight limits)Initiatives in place to address racial and ethnic disparities associated with PrEP uptake and persistence The role of on-demand PrEP in transgender individuals receiving gender-affirming hormone therapy Offering patient-centered care Educating healthcare professionals on how to prescribe PrEPFaculty: Jill Blumenthal, MD, MAS Associate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaKenric B. Ware, PharmD, MBA, AAHIVP Clinical Associate ProfessorDepartment of Pharmacy PracticeMercer University College of PharmacyAtlanta, GeorgiaLink to full program: https://bit.ly/3Fqdgs9

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Misconceptions about PrEP eligibility Strategies to improve lab monitoring on PrEP Leveraging patient navigators and clinic staff to expand PrEP accessData on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)Considerations for prescribing on-demand and same-day PrEP Addressing healthcare professional hesitancy to prescribe PrEPUS Preventive Services Task Force PrEP guideline updatesBundling sexually transmitted infection services with PrEPFacultyRaphael J. Landovitz, MD, MScProfessor of MedicineDivision of Infectious DiseasesDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services Los Angeles, CaliforniaHyman Scott, MDAssistant Clinical ProfessorDepartment of MedicineUniversity of California, San FranciscoClinical Research Medical DirectorBridge HIVSan Francisco Department of Public HealthSan Francisco, CaliforniaLink to full program: https://bit.ly/3PZGYdR

In honour of World Hepatitis Day, today we focus on the Hepatitis B virus (HBV), a virus that can be transmitted through contact with infected blood and from mother to child during labour. HBV can also be transmitted sexually. It infects liver cells and causes both acute and chronic infections, which can be severe. Since HBV was discovered in 1965, we have made great progress in reducing the burden of infections and disease through prevention and antiviral treatment, but much is left to do. The World Health Organization has called for enhanced efforts along four main pathways: i) increasing awareness of HBV infection, ii) promoting prevention strategies, iii) expanding access to testing and treatment; and iv) improving surveillance, data collection and research. Today we will discuss these topics with a focus on the European Region with our three guests: - Dr. Erika Duffell, Public Health Physician, the European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden - Prof. Anna Maria Geretti, Editor in Chief, STI journal; Professor & Consultant in Infectious Diseases & Virology, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy; North Middlesex University Hospital and King's College London, London, United Kingdom - Prof.  Simon de Lusignan, Senior Academic General Practitioner (GP) and Director of the Royal College of GPs Research & Surveillance Centre, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom Hosted by: Dr. Fabiola Martin, Sexual Health, HIV, HTLV specialist, BMJ STI Podcast Editor, Brisbane, Australia    Relevant papers: Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database https://www.journalofinfection.com/article/S0163-4453(23)00130-5/ Impact of maternal HIV–HBV coinfection on pregnancy outcomes in an underdeveloped rural area of southwest China https://sti.bmj.com/content/96/7/509 Prevalence of hepatitis B immunity and infection in home self-sampling HIV service users https://sti.bmj.com/content/98/4/286 Hepatitis A and B vaccination in gbMSM in Ireland: findings from the European MSM Internet Survey 2017 (EMIS-2017) https://sti.bmj.com/content/99/5/337 Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial https://sti.bmj.com/content/99/2/140 Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris https://sti.bmj.com/content/99/5/361    

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:How long someone can receive PrEP and the monitoring that is needed over timeRecommendations for monitoring bone health while receiving oral PrEPTreatment as prevention and PrEP efficacy data and options for people who inject drugsThe role of circumcision in HIV preventionThe use of PrEP in pregnancyConcern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP optionsThe possibility of using FTC/TAF on demandInequities in adherence and persistenceCost considerations with different PrEP modalitiesRecommendations for hospitalized patients receiving PrEPPrEP considerations for patients with renal dysfunction and higher BMIsPrEP efficacy based on site of exposurePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaJason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, MarylandLink to full program:https://bit.ly/3Fqdgs9

Do you know your STI status? This episode tackles the serious topic of HIV and sexual health with a side-splitting twist? Join our hosts as they navigate through the weird, wild, and wonderful world of HIV prevention, testing, and sexual well-being. From cringe-worthy stories to informative advice, we'll have you rolling on the floor laughing while empowering you to make smart choices. Let's turn awkward into awesome, serious into hilarious, and take a light-hearted approach to HIV and sexual health discussions. https://www.stdcheck.com/free-vs-paid.php?pid=9027250&iid=&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrIqCnLo9rTJHeUAnfza3LbxfqBSRbYE9DKmyNdvN3v5wKIfO8SeyvhoCUYsQAvD_BwE Don't forget to subscribe so you don't miss a sip! Join the Tastie Brew! https://www.instagram.com/obwpod/ https://www.tiktok.com/@obwpod https://twitter.com/obwpod https://www.youtube.com/channel/UCRL90mabprkIUvTWe-V6RWw Like who was on? Get connected! https://www.instagram.com/lucasmalaluan/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/obwpod/message

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, and Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discuss key considerations to barriers to PrEP uptake, including:Limited data on “on-demand” PrEP in cisgender women Strategies on improving communication with non‒English-speaking populations Role of pharmacists with injectable PrEP CDC PrEP guideline recommendations on routine HIV-1 RNA testing Engaging with pregnant persons who might want access to PrEP in the pharmacy settingOral PrEP efficacy based on adherence in cisgender women, including recent data presented at CROI 2023 by Marrazzo and colleaguesPresenters: Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCPAssociate ProfessorDepartment of Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisSystem-Level HIV/ID Clinical PharmacistAmbulatory PharmacyNorthwestern MedicineWheaton, IllinoisKevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCESAssistant ProfessorDepartment of Pharmacotherapy and Clinical ResearchUniversity of South FloridaClinical PharmacistTampa General Medical GroupTampa, FloridaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZjSFhgDownloadable slides: https://bit.ly/3PsFNDt

Join Dr. Dèsa Daniel and Dr. James García as they discuss health disparities in LGBTQ+ communities of color, and how mental health providers can advocate for better care and services. They also talk about their work with students, mentorship, and the importance of HIV PrEP medication. Tune in to learn more about the challenges faced by LGBTQ+ individuals seeking affirming care, and what can be done to address these issues.   For more on James, links from the conversation, and APA citation for this episode visit https://concept.paloaltou.edu/resources/the-thoughtful-counselor-podcast  The Thoughtful Counselor is created in partnership with Palo Alto University's Division of Continuing & Professional Studies. Learn more at concept.paloaltou.edu

In this episode, 2 HIV experts from the Asia-Pacific region share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.Specifically, the faculty discuss the role of newer innovations in HIV, including 2-drug oral antiretroviral therapy (ART) regimens, 2-drug long-acting injectable ART, and long-acting HIV pre-exposure prophylaxis in HIV care in the Asia-Pacific region, as well as the implications of weight gain with ART and important considerations related to the unique challenges associated with caring for the aging population of people with HIV in the region.Presenters:Anchalee Avihingsanon, MD, PhDHIV-NAT, Thai Red Cross AIDS Research CentrePathumwan, Bangkok, Thailand Senior Clinical TrialMedicineBangkok, ThailandReena Rajasuriar, BPharm, MPharm, PhDAssociate ProfessorDepartment of MedicineUniversity of MalayaKuala Lumpur, MalaysiaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare. Link to full program: bit.ly/3Hz0jNa 

Episode 132: Harm Reduction and Reproductive HealthMeghana explains how to implement harm reduction strategies in at-risk populations such as unhoused patients and injected drug users. Dr. Arreaza adds comments about PrEP for HIV and Expedited Partner Therapy (EPT)  Written by Meghana Munnangi, MPH, third-year osteopathic medical student, College of Osteopathic Medicine of the Pacific Western University of Health Sciences. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Arreaza: It can be frustrating for physicians trying to change “risky” behaviors in their patients and turn those behaviors into “healthy” behaviors. Doctors deal with this issue every day, but after reading more about the principle of harm reduction, I'm feeling more prepared to help our patients reduce their risks.What is harm reduction?Meghana: Harm reduction is a set of evidence-based interventions that arose within the public health community to reduce the harms associated with risky health behaviors. Most commonly, harm reduction refers to the policies and programs that aim to minimize the negative impacts associated with substance use disorder. The goal is to “meet people where they are” and to provide compassionate, judgment-free interventions and resources to at-risk populations.Examples of people who are part of the “at-risk population.”Some examples are injection-drug users and sex workers. With America experiencing the largest substance use and overdose epidemic we have ever faced, it is exceedingly important we provide services such as clean needle exchange, overdose reversal training, safer sex kits, and more to prevent unnecessary injury, disease, and death. Arreaza: In some countries where prostitution is legal, women are required to have regular check-ups to continue work. I see that as a harm-reduction strategy. I disagree with having sexual workers, but if we are unable to eliminate them, then harm reduction may be the way to go. Why is harm reduction important in medicine?Meghana: Healthcare providers have a unique opportunity to improve the quality of life and limit the negative outcomes associated with risky health behaviors by incorporating harm reduction strategies into their practice. Harm reduction interventions not only decrease health risks in an individual but also in the community. Examples of harm reduction strategies. Meghana: Studies have shown that areas that have introduced clean needle exchange interventions have lower HIV seroprevalence compared to areas that do not have similar interventions [1]. It is critical  as health care providers to respect our patient's choices and provide supportive care that will not deter patients from accessing care in the future. Patients who engage in risky activities often face stigma and are treated poorly by the medical system making behavioral changes even more difficult [2]. Understanding that many patients may not be willing to change their behaviors and using a practical approach to medical counseling can strengthen physician-patient relationships. Arreaza: I can think of another example. Pre-exposure prophylaxis for HIV in patients who have multiple sex partners. You wish those patients would have more insight into the risks associated with having multiple sexual partners, but if you cannot change them, you can still reduce the risk.What is harm reduction in the context of the reproductive health field?Meghana: Within Harm Reduction programs, there are many important strategies targeted toward improving sexual and reproductive health. Individuals who inject drugs and sex workers have limited access to family planning services and HIV testing. Studies have shown that individuals with substance use disorder have higher rates of unintended pregnancies, pregnancy-related mortality and morbidity, and lower rates of contraceptive use compared to the general population [3,4]. Harm reduction within the reproductive health field must include expanding access to condoms, contraceptive methods, STI and HIV testing, and prenatal care. Reproductive health harm reduction strategies can reduce rates of STIs, HIV, and unintended pregnancies. In addition to expanding access to condoms, STI screening, treatment, and partner therapy must be offered and encouraged to all patients. Arreaza: As a reminder to our listeners, Expedited Partner Therapy (EPT) consists in treating the partner(s) of a patient with chlamydia or gonorrhea. You, as a physician, treat a patient with STI, but you also give a prescription or medication to that patient, and he/she takes the prescription or medication to his/her partner(s) without me (the doctor) seeing the partner in the clinic or hospital. This is a harm-reduction strategy. It is permissible in 46 states in the US and potentially allowable in Alabama, Kansas, Oklahoma, and South Dakota. It is prohibited in 0 states. Meghana: Regarding birth control, a recent study by Dr. Frank and Dr. Morrison from the University of Michigan suggests that long-acting reversible contraceptives (LARCs) such as the Intrauterine Device (IUD) or the “Implant” should be offered and easily accessible to women with substance use disorder [5].  In America, around 45% of all pregnancies are unintended, and among women with substance use disorders, this number is doubled [6,7]. More so, women with substance use disorders are 25% less likely to use any form of contraception and are more likely to use less effective methods [5]. Patient autonomy is important.Meghana: Autonomy is one of the fundamental principles of ethics in medicine, so it is important that all contraceptive decisions are made without any form of coercion. Also, all discussions must take into consideration previous trauma, such as intimate partner violence. Contraceptive counseling should be comprehensive, and patients should be educated on all methods, including emergency contraception and barrier methods.  Patients should not be coerced into choosing a LARC simply because they engage in risky health behaviors and should be offered the same methods as the general population [8]. Arreaza: Let's remember to offer Nexplanon to unhoused patients. On the topic of emergency contraception, you can listen to episode 129. Now, please give us a conclusion.“If you can't fly then run, if you can't run then walk, if you can't walk then crawl, but whatever you do you have to keep moving forward.”― Martin Luther King Jr.Meghana: Overall, family physicians are in a unique position to incorporate harm reduction strategies into their practice to improve the quality of life of their patients and to improve health outcomes in their community. Reproductive health harm reduction strategies should be considered and offered to all patients who engage in risky health behaviors. Individuals with substance use disorder and sex workers should be routinely tested for STIs, including HIV and Hepatitis C, as well as offered pregnancy testing and prenatal care if needed. Comprehensive contraceptive counseling, including condom use and emergency contraception, should be discussed with all patients, and conversations should be stigma-free and collaborative. Incorporating reproductive health interventions into already existing harm reduction programs is key to improving the overall health and well-being of our most vulnerable communities. _____________________Conclusion: Now we conclude episode number 132, “Harm Reduction and Reproductive Health.” Meghana gave us an excellent introduction to the principles of harm reduction in medicine. Applied to reproductive health, we can reduce risk by improving access to condoms, HIV and STI tests, and birth control methods, especially IUD and subdermal implants. Dr. Arreaza also reminded us of strategies such as pre-exposure prophylaxis for HIV (PrEP) and Expedited Partner Therapy for STIs. This week we thank Hector Arreaza and Meghana Munnangi. Audio editing by Adrianne Silva.Even without trying, every night, you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you. Send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Amundsen EJ. Measuring effectiveness of needle and syringe exchange programmes for prevention of HIV among injecting drug users. Addiction. 2006;101:911–2. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2006.01519.x?sid=nlm%3ApubmedNyblade L, Stockton MA, Giger K, et al.; Stigma in health facilities: why it matters and how we can change it. BMC Med. 2019;17(1):25. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376713/.Woodhams E. Partners in contraceptive choice and knowledge. November 18, 2021. Available at https://picck.org/enduring-sud/.Patel P. Forced sterilization of women as discrimination. Public Health Rev. 2017;38:15. Available at https://publichealthreviews.biomedcentral.com/articles/10.1186/s40985-017-0060-9Frank CJ, Morrison L. Harm reduction for patients with substance use disorders. Am Fam Physician. 2022;105(1):90-92. Preview available at https://www.aafp.org/pubs/afp/issues/2022/0100/p90.html.Heil SH, Jones HE, Arria A, et al.; Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40(2):199-202. Preview available at https://pubmed.ncbi.nlm.nih.gov/21036512/.Terplan M, Hand DJ, Hutchinson M, et al.; Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med. 2015;80:23-31. Preview available at https://www.sciencedirect.com/science/article/abs/pii/S0091743515001140?via%3DihubBaca-Atlas MH, Nimalendran R, Baca-Atlas SN. Applying Harm Reduction Principles to Reproductive Health. Am Fam Physician. 2023 Jan;107(1):Online. PMID: 36689956. Available at https://www.aafp.org/pubs/afp/issues/2023/0100/letter-reproductive-health.html.Royalty-free music used for this episode: “Gushito - Burn Flow." Downloaded on October 13, 2022, from https://www.videvo.net/

In this episode, Darrell H. S. Tan, MD, FRCPC, PhD, and Kenric Ware, PharmD, AAHIVP, discuss considerations for HIV pre-exposure prophylaxis (PrEP) persistence, including:The PrEP continuum of care in the United States, including inequities in PrEP uptake and persistence by raceCDC PrEP guidance regarding PrEP indicationsPrEP eligibility by regimenSummary of renal, bone, and weight outcomes with different PrEP optionsData on HIV acquisition following PrEP discontinuationDrug concentrations and recommendations for stopping long-acting cabotegravir for PrEPExpanding PrEP options to facilitate adherence and persistenceProviding PrEP by telehealthPresenters:Darrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaKenric Ware, PharmD, AAHIVPAssociate ProfessorDepartment of Pharmacy PracticeSouth UniversitySavannah, GeorgiaChairperson, PharmacistBoard of DirectorsJoseph H. Neal Health CollaborativeColumbia, South CarolinaLink to full program:https://bit.ly/3HPu4Lk

In this episode I have an open and real discussion with Michael Williams (He/Him) who is a board-certified Advanced Practice Registered Nurse (APRN). As an Afro-Latino bilingual (English, Spanish) APRN specializing in Internal Medicine and HIV-PrEP, he has cared for a culturally and socio-economic diverse patient population for over six years. Along with clinical practice, Michael has been a clinical instructor at several institutions- Yale University, Texas State University, and Concordia University: Texas. He is also a Doctorate of Nurse Practitioner student at Louise Herrington School of Nursing: Baylor University. Michael credits his love for medicine to growing up in New York City and his parents. His upbringing exposed him to many healthcare challenges and obstacles to care firsthand. Being of Panamanian descent allowed him to see the importance of understanding culture and its impact on delivering care. These experiences led him to obtain the Bachelor of Science in Nursing ‘09 and Master of Science in Nursing ‘16 degrees at the University of Tampa. As a first-generation college graduate, he and four friends initiated an endowment scholarship for first-generation college students at their alma mater.Michael believes community care is essential to the advancement of society. The philosophy guiding his practice is to provide the highest level of care through meaningful and collaborative relationships with all community members. He actively participates in various community events: speaker on health-related topics, health fairs, 5k to half marathon races, and volunteering at the local food bank. He has also authored peer-reviewed poems related to social issues in the community. Michael firmly believes that improving healthcare outcomes begins with educating and empowering the community that he serves.Join the conversation by sending comments or questions to hello@stressblueprint.com. Put NWP in the subject line.1. Subscribe to the Nurse Wellness Podcast 2. Download your FREE resource 3 Question to Ask When You're Stressed 3. Join the Wellness Hub for Stress Solutions community4. Email Nurse Wellness Podcast at hello@stressblueprint.comIntro and outro music produced by DNMbeats

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations Key remaining questions related to PrEP options for cisgender women and people who inject drugsConcerns about resistance at seroconversion in patients with suboptimal PrEP complianceImplementation of molecular screening for patients receiving PrEPExpectations for weight gain and patient counseling pointsPresenters:Carolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficerAmerican Academy of HIV MedicineChief Clinical OfficerNational Clinician Consultation CenterSamantha Strong, PharmD, BCACP, AAHIVP, CDCES Clinical Director of PharmacyNevada Health CentersLas Vegas, NevadaLink to full program: https://bit.ly/3Fqdgs9

In this episode, Latesha Elopre, MD, MSPH, discusses key considerations to barriers to PrEP uptake, including:Addressing disparities among racial and ethnic minority populationsUnderstanding the concept of intersectionality Tackling multiple levels of intersectionalityIndividual (eg, self-stigma, mental health)Network (eg, access to PrEP services)Community (eg, racism, stigma, poverty)Social and structural (eg, laws/policies)Epidemic (eg, population level of viremia)Presenter: Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZjSFhgFollow along with the slides:https://bit.ly/3YmeRWy

Featuring articles on hydrochlorothiazide and the prevention of kidney stones, the treatment of severe scrub typhus, nicotinamide for skin-cancer chemoprevention, neoadjuvant pembrolizumab in advanced melanoma, cancer screening after paid-sick-leave mandates, and health care in U.S. correctional facilities; a Clinical Problem-Solving describing a rocky resurgence; and Perspective articles on investing in national HIV PrEP preparedness, on health care equity for undocumented immigrants, on the injury equity framework, and on aligning quality measures across CMS.

In this episode, 2 HIV experts from Latin America share their thoughts on the current status of HIV prevention strategies in the region, including recent successes and ongoing challenges. Specifically, the faculty discuss:Barriers that limit PrEP availability in many regions of Latin America despite the high need among vulnerable and at-risk groupsSuccessful expansion of PrEP access in BrazilKey findings from the prospective ImPrEP study evaluating implementation of same-day oral PrEP among men who have sex with men and transgender women in Brazil, Mexico, and PeruWhat long-acting PrEP could mean for at-risk groups in Latin America when it becomes availableImportant considerations for PrEP among TGW Presenters:Claudia P. Cortes MDAssociate ProfessorInfectious DiseasesUniversidad de ChileSantiago, ChileBeatriz Grinsztejn MD, PhD Diretora, STD/HIV Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro ChagasOswaldo Cruz Foundation Rio de Janeiro, BrazilContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E

 In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.  Presenters:Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of Melbourne  Consultant Infectious Diseases PhysicianAlfred Hospital and Royal Melbourne Hospital  Melbourne, AustraliaDon Smith, MDConjoint ProfessorSchool of Population MedicineUniversity of New South WalesSenior Staff SpecialistAlbion CentreSouth Eastern Sydney Local Health NetworkSydney, AustraliaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E  

In this episode, Kenric Ware, PharmD, AAHIVP, discusses the role of college campuses in HIV pre-exposure prophylaxis (PrEP) uptake for adolescents, including the following.PrEP awareness and educationVenues for ongoing PrEP conversations, including in-person dormitory discussions, virtual webinars, and social media conversationsCampus health clinics that are safe and trusting and minimize stigmaIndividualized approaches, including:Engaging local students in discussions of regional barriers and facilitators to PrEP uptake on their campusRecruiting PrEP ambassadors with social capital on campus, such as student athletes or sorority or fraternity leadersIdentifying faculty and administrator PrEP champions to amplify and provide continuity and support to student PrEP messagingKenric Ware, PharmD, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice South UniversitySavannah, GeorgiaChairperson, PharmacistBoard of DirectorsJoseph H. Neal Health CollaborativeColumbia, South Carolina See the full program at: http://bit.ly/3WhbBvZ

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses improving HIV pre-exposure prophylaxis accessibility and availability for PWID, including by:Integrating PrEP with services that PWID are already aware of and/or connected to (eg, harm reduction/syringe services and substance use disorder treatment programs, peer-based training/education initiatives, healthcare for the homeless programs, and emergency departments) Staffing PrEP programs with people who are trusted by PWID and delivering PrEP in settings where patients feel respected, comfortable, and safe Tailoring prescribing practices and interventions (eg, same-day medication initiation, on-site pharmacies and/or medication storage, and intensive outreach and navigation) to support the care needs of PWIDCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficeAmerican Academy of HIV MedicineSee the full program at: https://bit.ly/3WhbBvZ

In this episode,  Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, includingPrevention strategiesLA therapiesInvestigational agentsPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomBabafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on an online CME/CE program supported by an independent educational grant from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare. Link to full program:https://bit.ly/3iFEF0T

More than 7 million people in Somalia are in dire need of food assistance. And the UN has warned that famine there is “at the door." East Africa has had four straight failed rainy seasons, for the first time in more than half a century. That, combined with rising food prices exacerbated by the war in Ukraine, are endangering an estimated 20 million people in the Horn of Africa region. Plus, how a ruling on HIV PrEP meds could affect access to other preventative care. Guests: Axios' Laurin-Whitney Gottbrath, Emily Peck, and Tina Reed. Credits: Axios Today is produced by Niala Boodhoo, Sara Kehaulani Goo, Alexandra Botti, Lydia McMullen-Laird, Fonda Mwangi, Robin Linn, Alex Sugiura, and Ben O'Brien. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893. Go deeper: "Famine is at the door" in Somalia, UN aid chief warns Federal judge rules that mandated HIV PrEP coverage violates religious freedom Learn more about your ad choices. Visit megaphone.fm/adchoices

John discusses a ruling by a federal judge in Texas that the government cannot require a Christian-owned company to cover HIV preventative medication because it violates their religious rights under federal law. Two Christian-owned businesses in Texas claim the drugs encourage homosexual behavior. Then he interviews Madeline Ostrander, the author of “At Home on an Unruly Planet - Finding Refuge on a Changed Earth”, about the effects of climate change on our sense of home, community, tradition, and history. Next, he again welcomes Bob Cesca and they talk about the PrEP medication ruling in Texas and how "fake" Christians interpret the bible. Then finally he chats with Rich in Denver about dark money in politics.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode,  an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program:https://bit.ly/3P3uPBc

Adolescents represent a portion of the fastest growing demographic for development of sexually transmitted infection. Studies have found that STIs have some of the highest rates in individuals aged 15-24, and 20% of new HIV diagnoses occur in people aged 13-24. Pre-exposure prophylaxis (PrEP) is medicine people at risk for HIV take to prevent getting HIV from sex or injection drug use and is an effective tool to dramatically decrease the risk of HIV acquisition in at-risk youth. Dr. Cheryl Newman, a board certified infectious disease specialist joins medical students Patrice Collins and Elise Liu to discuss PrEP for HIV prevention in the adolescent population.  After listening to this podcast, learners should be able to: Learn the approach to sexual health screening in adolescents. Understand the risks of HIV exposure in adolescents. Define PrEP and how it works. Understand the requirements for starting PrEP, including demographics and preliminary testing. Explain the federal and/or state laws that govern the prescription of HIV prevention medicine for adolescents. FREE CME Credit (requires free sign-up):  https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=11407    References:  Agwu A. Sexuality, Sexual Health, and Sexually Transmitted Infections in Adolescents and Young Adults. Top Antivir Med. 2020;28(2):459-462. Centers for Disease Control and Prevention. Prep for HIV Prevention in the U.S. Accessed Apr 15, 2022. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. National Institute of Health. Updated Jun 03, 2021. Accessed Apr 15, 2022. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adolescents-and-young-adults-hiv#:~:text=Preventive%20Measures%20and%20Supporting%20Long,%2C%20osteoporosis%2C%20and%20neurocognitive%20impairment. Hsu K, Rakhmanina N. Adolescents and Young Adults: The Pediatrician's Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis. Pediatrics. 2022; 149(1):e2021055207 Hosek S, Henry-Reid L. PrEP and Adolescents: The Role of Providers in Ending the AIDS Epidemic. January 2020; 145 (1): e20191743. 10.1542/peds.2019-1743 Truvada Website. https://www.truvada.com/truvada-safety/clinical-studies. Accessed Apr 15, 2022. Descovy Website. https://www.descovy.com/#isi. Accessed Apr 15, 2022. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Dec 20, 2021. Accessed Apr 15, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Preention in Cisgender Men and Transgender Women. N Engl J Med. August 2021; 385:595-608. https://www.nejm.org/doi/full/10.1056/NEJMoa2101016 Highleyman L. US approves injectable cabotegravir for PrEP. Accessed Apr 15, 2022. https://www.aidsmap.com/news/dec-2021/us-approves-injectable-cabotegravir-prep Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women. Nov 9, 2020. Accessed Apr 15, 2022. https://www.who.int/news/item/09-11-2020-trial-results-reveal-that-long-acting-injectable-cabotegravir-as-prep-is-highly-effective-in-preventing-hiv-acquisition-in-women FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. Oct 3, 2019. Accessed Apr 15, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic#:~:text=The%20U.S.%20Food%20and%20Drug,who%20have%20receptive%20vaginal%20sex Centers for Disease Control and Prevention. Pre-exposure Prophylaxis (PrEP). Accessed Apr 15, 2022. https://www.cdc.gov/hiv/clinicians/prevention/prep.html#:~:text=For%20oral%20PrEP&text=Assess%20creatinine%20clearance%20once%20every,creatinine%20clearance%20every%206%20months Tanner M, Miele P, et al. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020. CDC Recommendations and Reports. 2020; 69(3):1-12 Cowan EA, McGowan JP, Fine SM, et al. Diagnosis and Management of Acute HIV [Internet]. Baltimore (MD): Johns Hopkins University; 2021 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563020/ Sax PE. Screening and diagnostic testing for HIV infection. In: Post TW, ed. UpToDate; 2022. Accessed May 15, 2022. https://www.uptodate.com/contents/screening-and-diagnostic-testing-for-hiv-infection?search=hiv%20screening&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 Jaspard M, Le Moal G, Saberan-Roncato M, Plainchamp D, Langlois A, Camps P, Guigon A, Hocqueloux L, Prazuck T. Finger-stick whole blood HIV-1/-2 home-use tests are more sensitive than oral fluid-based in-home HIV tests. PLoS One. 2014 Jun 27;9(6):e101148. doi: 10.1371/journal.pone.0101148. PMID: 24971842; PMCID: PMC4074152. NBC News. 2022. PrEP, the HIV prevention pill, must now be totally free under almost all insurance plans. [online] Available at: [Accessed 19 May 2022].

We recap the top pearls from ACP #IM2022 including important drug interactions/intolerance (acetaminophen, tramadol, ticagrelor, nirmatrelvir-ritonavir), perioperative medicine (bridging, DOAC reversal agents, dental procedures, MINS), recognizing PMR, when to initiate urate-lowering therapy in gout, glucocorticoid-induced osteoporosis, food as medicine, dietary potassium, OSA, nocturia, telemedicine and health equity, a new obesity medicine paradigm, advances in HIV/PrEP, and rethinking atrial fibrillation!  Note: Due to a rapid turnaround there is no CME for this episode, but visit curbsiders.vcuhealth.org to claim credit for past episodes. Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Show Segments Intro Tapering long-term opioids Physician Wellbeing Common drug interactions (acetaminophen, ticagrelor, tramadol, Nirmatrelvir-ritonavir) Perioperative medicine (bridging, DOAC reversal agents, dental procedures, MINS) Nocturia and OSA Food as Medicine Rheumatology (how to diagnose PMR, when to initiate ULT for gout and steroid-induced osteoporosis) Avi's pearls on (diversity, telemedicine, telehealth, burnout) Obesity medicine (a new paradigm and a new medication) HIV in primary care (PrEP, long-acting injectable antiviral therapy) Atrial fibrillation Outro Credits Written, Produced, and Hosted by: Nora Taranto MD; Molly Heublein MD; Chris Chiu MD, FACP, FAAP; Avital O'Glasser MD, FACP; Alan Dow MD, FACP; Matthew Watto MD, FACP; Paul Williams MD, FACP   Show Notes: Matthew Watto MD, FACP Cover Art: Chris Chiu MD, FACP, FAAP Production team: Pod Paste Sponsor: Indeed Visit indeed.com/internalmedicine to claim you $75 credit now. Sponsor: Locumstory Visit Locumstory.com to learn more about locums